Analysts deem AstraZeneca-BMS merger unlikely despite market buzz

Analysts say that talks between AstraZeneca and Bristol Myers Squibb are unlikely to result in a merger because the two companies have overlapping product lines that would attract heavy antitrust scrutiny.

AstraZeneca's stock fell more than 4% in pre‑market trading, while Bristol Myers Squibb shares rose about 6% following the news of the rumored talks.

If the merger were to happen, it would become the largest deal in pharmaceutical history, but analysts remain skeptical that regulatory hurdles and business overlap will prevent it from materializing.